SUBCUTANEOUS SUMATRIPTAN DOES NOT ABORT ATTACKS OF CHRONIC PAROXYSMAL HEMICRANIA (CPH)

被引:28
作者
DAHLOF, C
机构
[1] Gothenburg Migraine Clinic, Uppgång D Göteborg
来源
HEADACHE | 1993年 / 33卷 / 04期
关键词
D O I
10.1111/j.1526-4610.1993.hed33040201.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:201 / 202
页数:2
相关论文
共 6 条
[1]   SUMATRIPTAN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN THE ACUTE TREATMENT OF MIGRAINE AND CLUSTER HEADACHE [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1992, 43 (05) :776-798
[2]   PRECLINICAL STUDIES ON THE ANTIMIGRAINE DRUG, SUMATRIPTAN [J].
HUMPHREY, PPA ;
FENIUK, W ;
MARRIOTT, AS ;
TANNER, RJN ;
JACKSON, MR ;
TUCKER, ML .
EUROPEAN NEUROLOGY, 1991, 31 (05) :282-290
[3]   5-HYDROXYTRYPTAMINE AND THE PATHOPHYSIOLOGY OF MIGRAINE [J].
HUMPHREY, PPA .
JOURNAL OF NEUROLOGY, 1991, 238 :S38-S44
[4]  
ROSE FC, 1990, J ROYAL SOC MED, V84, P519
[5]   FROM SEROTONIN RECEPTOR CLASSIFICATION TO THE ANTIMIGRAINE DRUG SUMATRIPTAN [J].
SAXENA, PR ;
FERRARI, MD .
CEPHALALGIA, 1992, 12 (04) :187-196
[6]  
SJAASTAD O, 1987, MIGRAINE CLIN THERAP, P13552